Silo Pharma's QwikAgents joins AMD AI developer program to accelerate AI agent platform

Why Is Silo Pharma Stock Volatile Today? - SILO Pharma (NASDAQ:SILO)

Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership Silo Pharma shares initially traded higher on Tuesday before pulling back and turning negative. The company said participation in the program is expected to support the continued development, testing, optimization, and benchmarking of QwikAgents' artificial intelligence workloads as it broadens the platform's consumer and enterprise capabilities. Platform Targets Individuals, Developers And Businesses QwikAgents is building a next-generation AI agent platform designed to provide dedicated, persistent AI agents for individuals, developers, small businesses, and enterprises. According to the company, users can deploy blank AI agents and, in the future, purpose-built agents for tasks including research, content generation, scheduling, coding, browser automation, and workflow automation. Starter plans are expected to begin at $14 per month, with infrastructure options that scale for more demanding workloads. The platform is also being designed to combine persistent memory, dedicated agent infrastructure, smart model routing, and encrypted backups with a simplified deployment process. Silo Pharma said these features are intended to provide configurable AI agents across personal, developer, and business workflows. AMD Program Expected To Support Platform Scaling Silo Pharma expects access to AMD's developer resources to help improve platform performance, increase agent reliability, and support the scalable deployment of autonomous AI agents capable of reasoning, executing tasks, and completing workflows with minimal human intervention. Beyond its AI initiative, Silo Pharma remains a developmental-stage biopharmaceutical company focused on therapies for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Its pipeline includes SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical program targeting Alzheimer's disease. SILO Price Action: SILO Pharma shares were down 4.36% at $5.05 at the time of publication on Tuesday, according to Benzinga Pro data. Image via Shutterstock Market News and Data brought to you by Benzinga APIs To add Benzinga News as your preferred source on Google, click here.

Silo Pharma subsidiary joins AMD AI developer program By Investing.com

SARASOTA, Fla. - Silo Pharma (NASDAQ:SILO) announced today that its subsidiary QwikAgents has been accepted into the AMD AI Developer Program, according to a press release statement. The stock closed at $5.28, down 6.7% over the past week, though InvestingPro analysis suggests the company appears undervalued at current levels. With a market capitalization of $5.73 million, the developmental-stage company maintains a strong current ratio of 9.65. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a developer community. QwikAgents is developing an AI agent platform designed for individuals, developers, small businesses and enterprises. The platform is being built to enable users to deploy AI agents for research, content generation, scheduling, coding, browser automation and workflow automation. Starter plans are set to begin at $14 per month, with scalable infrastructure options for advanced workloads. According to InvestingPro Tips, while Silo holds more cash than debt on its balance sheet, analysts do not anticipate profitability this year. Subscribers have access to 6 additional ProTips for deeper investment insights. "Joining the AMD AI Developer Program represents what we believe is an important step in advancing our QwikAgents platform," said Eric Weisblum, Chief Executive Officer of Silo Pharma. QwikAgents plans to use AMD's developer resources for development, hosting, testing, optimization, benchmarking and potential training of AI agent workloads as the platform expands. The platform is designed to combine persistent memory, dedicated agent infrastructure, smart model routing, and encrypted backups. QwikAgents aims to support deployment of AI agents capable of executing tasks and completing workflows. Silo Pharma is a developmental-stage biopharmaceutical company focused on stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes programs such as SPC-15 for post-traumatic stress disorder, SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer's disease. QwikAgents is a wholly owned subsidiary of Silo Pharma. In other recent news, Silo Pharma has announced a private placement offering expected to generate approximately $4 million in gross proceeds. The company has entered into definitive agreements for the issuance of 619,965 shares of common stock or pre-funded warrants at a purchase price of $6.452 per share. This offering also includes Series A-3 and Series A-4 warrants to purchase up to 619,965 shares each at an exercise price of $6.21 per share. In addition, Silo Pharma reported that its investigational intranasal treatment, SPC-15, has shown stability over nine months of real-time testing. The stability data indicates that SPC-15 maintains its physical, chemical, and microbiological integrity under specified storage conditions. Furthermore, Silo Pharma's wholly owned subsidiary, QwikAgents, has joined the NVIDIA Developer Program, which provides access to NVIDIA's AI software ecosystem and technical resources. The company has also regained compliance with Nasdaq's minimum closing bid price requirement, as confirmed by the Nasdaq Stock Market LLC. These developments reflect Silo Pharma's ongoing efforts in both financial and technological advancements. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.